Psoriatic Arthritis - Vandalia OH (Metro Dayton)

Summary:

Click image to enlarge

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) and/or intolerance to a prior anti-tumor necrosis factor (TNF) by assessing the reduction in signs and symptoms of PsA.

--Have active Psoriatic Arthritis for at least 6 months

-- Have active plaque psoriasis

--Have an inadequate response and/or intolerance to anti-tumor necrosis factor alpha (TNF alpha) therapy, defined as presence of active PsA despite previous treatment with one prior anti-TNF alpha agent

--Does not have an inflammatory disease that might confound the evaluations of benefit of guselkumab therapy, including but not limited to RA, AS/nonradiographic AS, SLE, or Lyme disease.

--Has not received more than 1 prior anti-tumor necrosis factor (TNF) alpha agent (or biosimilars)

--Has never received Janus kinase (JAK) inhibitor including but not limited to tofacitinib, baricitinib, filgotinib, peficitinib, decernotinib, upadacitinib or any other investigational JAK inhibitor

Qualified Participants May Receive:

STAT Research will cover the cost of any trial related medical examinations and labs. 

You will be monitors and cared for during the course of the study by our professional staff and physicians.

No insurance required. 

You may receive a stipend for travel reimbursement and reasonable expenses.